Добро пожаловать
Нажатие «Авторизоваться» означает, что вы соглашаетесь с Условия использования и политика конфиденциальности Cointime.
Зарегистрировать аккаунт
Аккаунт уже существует?
Нажатие «page.Sign up» означает, что вы соглашаетесь с <a class="underline" href="#term-of-service">Условия использования</a> и a class="underline" href="#privacy-policy">политика конфиденциальности</a> Cointime.
Войдите, используя email
Зарегистрируйтесь с помощью email
твой почтовый ящик
Проверь свои входящие
Нажмите на ссылку в , чтобы войти.
Нажмите на ссылку в , чтобы зарегистрироваться.
Octant Bio
company
About
Octant Bio is a developer of synthetic technology used to improve health and treat disease.
- 11 - 50
Details
- Last Funding Type
- Series B
- Last Funding Money Raised
- $80M
- Industries
- Biotechnology,Life Science
- Founded date
- Jan 1, 2017
- Number Of Employee
- 11 - 50
- Operating Status
- Active
Octant Bio is a developer of synthetic technology used to improve health and treat disease. Its technology uses synthetic biology, genome engineering, next-generation sequencing, and computational tools to simultaneously measure the activity of thousands of receptor pathways in human cells that enable scientists to apply machine learning methods to engineer small molecules that interact with multiple receptors and unlock a new potential to treat complex diseases.
Funding Rounds
Number of Funding Rounds
Total Funding Amount
2
$110M
Octant Bio has raised a total of
$110M
in funding over 2 rounds. Their latest funding was raised on
Apr 28, 2022 from a Series B round.
| Announced Date | Round | Money Raised | Number of Investors | Lead Investors | Post Valuation | |
|---|---|---|---|---|---|---|
| Apr 28, 2022 | Series B | $80M | 1 | — | — | Detail |
| May 21, 2020 | Series A | $30M | 1 | — | — | Detail |
Investors
Number of Lead Investors
Number of Investors
—
1
Octant Bio is funded by 1 investors.
Allen & Company
are the most recent investors.
| Investor Name | Lead Investor | Funding Round |
|---|---|---|
Allen & Company
|
— | Series B |
Share
Twitter
LinkedIn
Line
Facebook
Telegram
Email
Page Link
